CRISPR Epigenetic Editing: Safely Reactivating Genes for Sickle Cell and Cancer’s Future

A new form of CRISPR technology developed by researchers at the University of New South Wales (UNSW Sydney) and St Jude Children’s Research Hospital promises a safer path for treating genetic diseases by controlling genes without cutting DNA strands. Published in Nature Communications, the study demonstrates epigenetic editing that removes methyl groups (small chemical clusters attached to DNA) from silenced genes, reactivating them precisely and reversibly. Lead researcher describes these methyl groups not as passive “cobwebs” but as active “anchors” that directly cause gene repression, settling a decades-long scientific debate.

The breakthrough targets inherited blood disorders like Sickle Cell disease, where mutations in the adult globin gene produce dysfunctional red blood cells, leading to chronic pain, organ damage, and reduced life expectancy. Rather than repairing the faulty gene, a risky process involving DNA cuts, the method reactivates the fetal globin gene, which naturally produces functional hemoglobin during fetal development but becomes methylated and silenced after birth. In laboratory tests on human cells, the team used a modified CRISPR system to deliver demethylation enzymes directly to the fetal globin promoter. Removing the methyl tags switched the gene on; re-adding them silenced it again, confirming methylation’s causal role.

The therapeutic workflow is elegantly straightforward. Doctors would extract a patient’s blood stem cells, apply epigenetic editing in the lab to erase methyl tags from the fetal globin gene, then reinfuse the cells into bone marrow. There, the edited stem cells would generate healthy red blood cells carrying fetal hemoglobin, bypassing the defective adult version entirely.

While the immediate focus remains on Sickle Cell and beta-thalassemia, the platform’s precision opens doors to broader genetic diseases where gene activation or silencing through methylation changes could restore function without altering DNA sequence. All work to date has occurred in controlled laboratory settings with human cells; animal studies and clinical trials lie ahead, potentially within a few years if preclinical validation succeeds.

From an oncology perspective, the implications are intriguing but longer-term. Cancer cells frequently silence tumor suppressor genes like CDKN2A, MLH1, and VHL through promoter hypermethylation, contributing to uncontrolled growth, immune evasion, and treatment resistance. Existing epigenetic drugs like azacitidine and decitabine broadly reduce methylation and work in blood cancers, but their non-specific effects limit use in solid tumors. This targeted CRISPR approach could, in principle, reactivate individual tumor suppressors or restore MHC expression to make “cold” tumors visible to immunotherapy without the mutagenesis risks of DNA-cutting tools. Preclinical studies in hepatocellular carcinoma have already shown related CRISPR activation reactivating methylated suppressors, suggesting potential for patient-specific panels targeting multiple silenced genes. However, oncology’s complexity (heterogeneous tumors, delivery challenges to solid masses) means direct clinical application remains distant compared to the clearer path for blood disorders.

Source.